Longevity & Mitochondria

NAD+

Also known as Nicotinamide adenine dinucleotide, NAD, Beta-NAD, beta-Nicotinamide adenine dinucleotide, NAD+ IV, Coenzyme I, Diphosphopyridine nucleotide (DPN)

A coenzyme rather than a peptide, given as a long intravenous drip or an injection, whose reputation rests almost entirely on animal work and on oral precursor trials rather than on studies of the injected molecule itself.

How it works

Nicotinamide Adenine Dinucleotide — a coenzyme critical for cellular energy production, DNA repair, and sirtuin activation.

Performance edge

Core longevity molecule; boosts mitochondrial function, mental clarity, and recovery.

Plain-English guide

NAD+, without the jargon

What it is

NAD+ is short for nicotinamide adenine dinucleotide, and the first thing to say plainly is that it is not a peptide at all: it is a coenzyme, a small molecule built from two nucleotides that your cells already make from vitamin B3 and use in almost every energy-producing reaction. It sits alongside peptides on sites like this one because it is sold by the same clinics in the same kind of vial, not because it belongs to the same chemical family. Every cell carries it, and the amount measured in tissue tends to fall with age, which is the observation the whole industry is built on. What is sold is either a slow intravenous drip, usually 250 to 1000 milligrams over one to several hours, or a subcutaneous or intramuscular injection of a compounded solution. It is not approved as a medicine anywhere for longevity, energy or mental clarity.

What people use it for

General anti-ageing and longevity drips, which is where most of the marketing sits and where no controlled human trial of the injected form exists
Energy, fatigue and mental clarity, claims that come from clinic reports and from oral precursor studies rather than from trials of infused NAD+
Recovery from training, on the reasoning that mitochondria need NAD+ to make adenosine triphosphate, the cell's energy currency
Heart failure after a heart attack, the one indication with a randomised placebo-controlled trial of intravenous NAD+ behind it (Am J Cardiovasc Drugs, 2026)
Addiction and withdrawal programmes, where multi-day high-dose drips are offered but no controlled trial was located in this search

How it works, simply

Think of NAD+ as the rechargeable battery pack your cells pass around to move energy from the food you eat to the machinery that uses it. A second set of jobs drains those packs for good: repair crews that fix broken DNA, and signalling enzymes that regulate ageing, consume NAD+ rather than just borrowing it. The pitch for a drip is that you are topping the packs back up from outside. The awkward detail is that the pack is too big and too charged to be carried through a cell wall intact, so it has to be taken apart at the door and rebuilt inside, which means an infusion is really a fast, expensive way of delivering the same building blocks a vitamin B3 pill delivers slowly.

What to expect, and when

During dripIn the only published comparison of commercially administered drips, all six people receiving 500 milligrams of NAD+ reported moderate to severe abdominal cramping, nausea, vomiting, a faster heart rate and chest pressure while it ran, and everything settled the moment the bag finished (Front Aging, 2026).
First 2 hoursNothing measurable happens in the blood. At an infusion rate of 3 micromoles per minute, plasma NAD+ and its breakdown products did not change for two hours, because the molecule was being cleared from plasma as fast as it went in (Front Aging Neurosci, 2019).
Hours 2-6Breakdown products appear and the kidneys start excreting NAD+ itself and methylnicotinamide. That is a description of where the dose went, not evidence that anything inside a cell improved.
Days 1-7Clinic protocols run consecutive daily infusions, and the heart failure trial used seven daily doses. No published study of injected NAD+ reports what healthy people feel across a loading week, so the energy and clarity claims made for this window are anecdote.
After month 1Follow-up runs to thirty days in the tolerability study and six months in the heart failure trial, and no longer-term study of injected NAD+ in healthy people has been published at all.

Side effects and interactions

Abdominal cramping, diarrhoea, nausea and vomiting during infusion, reported by all six NAD+ drip recipients in the 2026 Frontiers in Aging chart review
Chest pressure and a raised heart rate during infusion in the same six people, which is why clinics let clients slow their own drip rate
Throat pain and nasal congestion during infusion, also reported in that series
Infusions that drag on because of symptoms: 97 minutes on average for NAD+ against 37 minutes for the same dose of nicotinamide riboside
Dizziness: one participant in the 180-person heart failure trial had minor dizziness on a 10 milligram intravenous dose and treatment was stopped, with no liver, kidney or glucose abnormalities seen in that trial
No adverse events were reported in the 2019 six-hour pharmacokinetic infusion, where the rate was much slower at roughly 2 milligrams per minute, which suggests rate matters more than total dose for tolerability
The ordinary risks of any intravenous line, including bruising, phlebitis, infection and fluid overload, which are procedural rather than specific to this molecule

Who should avoid it

You are pregnant, trying to conceive, or breastfeeding; no human reproductive data exists for infused or injected NAD+
You have a current or past cancer diagnosis. A 2020 benefit-risk systematic review specifically names tumorigenesis, accumulation of putative toxic metabolites and promotion of cellular senescence as theoretical risks of raising NAD+ levels (Exp Gerontol, 2020)
You have known arrhythmia, angina or other unstable cardiac disease, given that chest pressure and a rising heart rate were universal during infusion in the one tolerability series located
You are a competitive athlete under the World Anti-Doping Agency code. A typical 500 millilitre drip breaches section M2.2, which prohibits intravenous infusions of more than 100 millilitres per 12 hours outside hospital treatment, surgery or clinical diagnostic investigation
You are considering running it at home rather than in a clinical setting, or you are not working with a physician who knows you are taking it

Common mistakes

Reading oral precursor research as evidence for the drip. The 2026 PRISMA-guided systematic review screened 113 studies and found no outcomes trial of intravenous or intramuscular NAD+ for anti-ageing or wellness; every human wellness result it could include used oral nicotinamide riboside or nicotinamide mononucleotide instead.
Pushing the infusion rate to get it over with. The published symptom profile tracks rate more than dose: a fast 500 milligram drip produced severe gastrointestinal symptoms and chest pressure, while 750 milligrams delivered over six hours produced none.
Treating it as a peptide and reconstituting it like one. It is a coenzyme, it is unstable in aqueous solution, and it degrades with heat, light and repeated freeze-thaw, so material prepared in advance and left at room temperature is not what the label says.
Self-administering intravenously. This is one of the few items on the site that involves a venous line and a multi-hour bag, and the sterility, air-embolism and fluid-volume risks belong to a clinical setting, not a kitchen.
Assuming more is better. A 2026 modelling review concluded that NAD+ responses are nonlinear and subject to feedback and biological saturation rather than following a simple dose-response curve (Mol Biol Rep, 2026).

Deep research

What the literature actually shows

Mechanism

NAD+ is a pyridine nucleotide present in every living cell, and it does two structurally different jobs. As a redox cofactor it cycles between NAD+ and NADH, carrying electrons through glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation, and in that role it is recycled rather than used up. As a substrate it is destroyed: sirtuins, poly-ADP-ribose polymerases involved in DNA repair, and the ectoenzyme CD38 all cleave NAD+ to do their work, releasing nicotinamide. Cells replace what is destroyed through the salvage pathway, in which nicotinamide phosphoribosyltransferase is rate-limiting, and to a lesser extent through de novo synthesis from tryptophan by way of the kynurenine pathway (Exp Gerontol, 2020).

The premise of supplementation is that tissue NAD+ falls with age and that restoring it restores the enzymes that depend on it. That premise is well supported in rodents: the 2026 PRISMA-guided review found that across 80 rodent studies NAD+ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory and functional outcomes, although effects varied by model and endpoint (Ageing Res Rev, 2026). The step that does not follow automatically is that pushing the finished coenzyme into a vein reproduces those effects in a person.

The pharmacokinetic evidence says the infused molecule does not simply arrive intact. In eleven men given 750 milligrams of NAD+ over six hours, neither plasma NAD+ nor its metabolites nicotinamide, methylnicotinamide, adenosine diphosphate ribose and nicotinamide mononucleotide changed at all for the first two hours, which the authors read as rapid and complete removal of NAD+ from the plasma. The metabolite pattern that later appeared was consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity, and what came out in urine at six hours was NAD+ itself and methylnicotinamide but, notably, not nicotinamide (Front Aging Neurosci, 2019). In other words the dose is dismantled at the cell surface and partly excreted, and the drip is better understood as an unusually rapid way of delivering precursors than as direct repletion.

Route also changes the shape of the exposure. A 2026 review combining literature synthesis with mathematical modelling concluded that continuous oral administration produces sustained NAD+ elevation whereas intravenous pulses generate transient increases with limited long-term accumulation, and that the dose-response relationship is nonlinear, shaped by feedback and biological saturation and modified by age and metabolic state (Mol Biol Rep, 2026). That is the mechanistic reason a weekly or thrice-weekly drip cannot be assumed to do what a daily oral precursor does, in either direction.

Strength of evidence

Human trialsThree human studies of injected NAD+ itself were located, one of them a 180-person randomised placebo-controlled trial, which meets the bar for this label; but that controlled trial gave 10 milligrams a day for seven days to heart failure patients rather than a wellness dose to healthy people, the other two are an eleven-man pharmacokinetic pilot and a fourteen-client chart review, and the 2026 PRISMA review states that no outcomes trial of intravenous or intramuscular NAD+ exists for the longevity, energy and clarity claims this compound is actually sold on — and no published human study has used the subcutaneous or intramuscular route, or the 50 to 100 milligram once-to-thrice-weekly schedule the cheatsheet figures describe; all three human studies of NAD+ itself were intravenous infusions.

Key studies

Randomised controlled trial2026American Journal of Cardiovascular Drugsn = 180
Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial
Adults with ischemic cardiomyopathy, a left ventricular ejection fraction of 45 percent or less and New York Heart Association class II-III were randomised to intravenous NAD+ at 10 milligrams per day in 100 millilitres of fluid, or matching placebo, for seven days on top of guideline-directed therapy. At one month the NAD+ group had a higher ejection fraction (45.44 versus 42.44 percent, p = 0.024). Every secondary endpoint, including six-month major adverse cardiac and cerebrovascular events, N-terminal pro B-type natriuretic peptide and functional class, moved in the same direction but did not reach significance. Single centre, and the dose is roughly fiftyfold below what wellness clinics infuse.
Human trial2019Frontiers in Aging Neurosciencen = 11
A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD
Eleven men aged 30 to 55 received either 750 milligrams of NAD+ in saline over six hours (eight men) or saline alone (three men). Plasma NAD+ and its metabolites did not change for the first two hours, indicating that infused NAD+ is cleared from plasma as fast as it is delivered; increased urinary excretion of NAD+ and methylnicotinamide, but not nicotinamide, appeared at six hours. No adverse events were observed at this slow infusion rate. The study measured where the dose goes and reported no clinical outcome.
Observational (human)2026Frontiers in Agingn = 14
Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
A chart review at a commercial wellness chain compared four consecutive daily infusions of 500 milligrams of NAD+ (six clients) against the same dose of nicotinamide riboside (eight clients), each in 500 millilitres of saline with clients controlling their own infusion rate. All six NAD+ recipients reported moderate to severe abdominal cramping, diarrhoea, nausea, vomiting, raised heart rate, throat pain, congestion and chest pressure during infusion, all resolving at the end of the bag; NAD+ infusions averaged 97 minutes against 37 for nicotinamide riboside. Liver enzymes, high-sensitivity C-reactive protein, renal markers and thyroid-stimulating hormone were unchanged at 30 days. The authors were employees of the company providing the infusions.
Review2026Ageing Research Reviews
NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence
A systematic review of 113 eligible intervention studies published between January 2010 and October 2025, comprising 33 human studies (28 randomised) and 80 rodent studies. Oral nicotinamide riboside and nicotinamide mononucleotide consistently raised circulating and cellular NAD-related metabolites and were generally well tolerated, but effects on functional, metabolic and vascular outcomes were heterogeneous and often null. The review states directly that no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-ageing or wellness, and classified the intravenous NAD+ pharmacokinetic pilot as contextual evidence only.
Review2026Acta Dermatovenerologica Alpina, Pannonica et Adriatica
Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility
A critical review of intravenous longevity drips including NAD+ found that the supporting evidence comes from preclinical models and small clinical series reporting transient reductions in oxidative biomarkers and modest improvements in fatigue, drawn from disease-specific or aesthetic contexts rather than healthy ageing populations. Few studies use validated ageing biomarkers such as epigenetic age or telomere length, placebo-controlled trials are scarce and underpowered or conflicting, and infusion protocols are highly heterogeneous. The authors conclude that intravenous longevity therapy should be regarded as experimental rather than evidence-based.
Review2026Molecular Biology Reports
NAD+ biology and supplementation: From mechanisms to clinical perspectives
A review combined with mathematical modelling of NAD+ kinetics. It reports that oral precursors reliably raise circulating NAD+ while clinical benefits remain variable and context-dependent, and states that intravenous NAD+ administration is less well characterised and lacks robust clinical validation. The model shows continuous oral dosing producing sustained elevation against transient increases with limited accumulation from intravenous pulses, with nonlinear responses governed by feedback and biological saturation.
Review2020Experimental Gerontology
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis
A systematic review that screened 1545 articles and included 147 of them (113 preclinical, 34 clinical). Nicotinamide, nicotinamide riboside and nicotinamide mononucleotide, and to a lesser extent NAD+ and NADH, showed favourable outcomes in age-related disorders linked to oxidative stress, inflammation and impaired mitochondrial function, with a limited acute toxicity profile. The authors state that evidence remains quite limited and long-term human trials are nascent, and name accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence as potential risks of raising NAD+ levels.
Randomised controlled trial2018Nature Communicationsn = 30
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
A two-by-six-week randomised, double-blind, placebo-controlled crossover trial in healthy middle-aged and older adults found that oral nicotinamide riboside was well tolerated and effectively stimulated NAD+ metabolism, with initial signals for reduced blood pressure and arterial stiffness that the authors flagged for future trials. This is the kind of controlled human evidence that exists for an oral precursor, and it is listed here as context: nicotinamide riboside is a different molecule given by a different route, so it says nothing directly about infused NAD+.

Safety data

Tolerability during the infusion is the best-documented harm and it is not minor. In the only published comparison of commercially administered drips, every one of the six people receiving 500 milligrams of NAD+ in 500 millilitres of saline reported moderate to severe abdominal cramping, diarrhoea, nausea, vomiting, an increased heart rate, throat pain, congestion and chest pressure, and slowed their own drip in response, stretching the average infusion to 97 minutes against 37 minutes for the same dose of nicotinamide riboside. All symptoms resolved when the bag finished (Front Aging, 2026). The pattern appears to track infusion rate rather than total dose: 750 milligrams given over six hours at roughly 2 milligrams per minute produced no adverse events at all (Front Aging Neurosci, 2019), and 10 milligrams over 40 to 60 minutes produced one case of minor dizziness in 90 patients (Am J Cardiovasc Drugs, 2026).

Short-term laboratory safety looks unremarkable in the small datasets available. The chart review found no significant change in alanine aminotransferase, aspartate aminotransferase, high-sensitivity C-reactive protein, urea and creatinine, or thyroid-stimulating hormone across 30 days, with a fall in alkaline phosphatase that stayed inside the reference range and a fall in high-density lipoprotein cholesterol whose meaning is unclear. The heart failure trial reported no notable effect on liver function, kidney function or glucose. Both datasets are small and short, and either uncontrolled or from a single centre; neither says anything about repeated infusions over months or years.

The longer-term risks are theoretical and unstudied rather than reassuring. A 2020 benefit-risk systematic review of 147 studies concluded that evidence was quite limited and long-term human trials nascent, and listed accumulation of putative toxic metabolites, tumorigenesis and promotion of cellular senescence as potential risks of raising NAD+ levels (Exp Gerontol, 2020); poly-ADP-ribose polymerase-driven DNA repair and sirtuin signalling are both processes cancer cells exploit, and nobody has given repeated high-dose infusions to people with a cancer history and followed them. Separately, injectable NAD+ is a compounded preparation rather than an approved product, so purity, sterility and actual content vary by pharmacy, and a 2026 critical review of intravenous longevity therapy concluded that the practice should be treated as experimental given underpowered or conflicting placebo-controlled data, pharmacokinetic limitations, procedural risks and highly heterogeneous protocols (Acta Dermatovenerol Alp Pannonica Adriat, 2026).

Regulatory status

FDA: As of 2026-09-19, injected or infused NAD+ is not approved by the US Food and Drug Administration for any indication and reaches patients only through compounding pharmacies; on the agency's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026, nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide disodium reduced (NADH) sit in Category 1, substances still under evaluation, while beta-nicotinamide adenine dinucleotide disodium salt trihydrate sits in Category 3, nominated without adequate support.
WADA: As of 2026-09-19, NAD+ is not named as a prohibited substance anywhere on the World Anti-Doping Agency Prohibited List, but method M2.2 prohibits intravenous infusions or injections totalling more than 100 millilitres per 12-hour period outside hospital treatment, surgery or clinical diagnostic investigation, so a standard 250 to 500 millilitre NAD+ drip is a prohibited method at all times even though the molecule in the bag is not banned.
Source: https://www.fda.gov/media/94155/download

Open questions

Does an intravenous infusion actually raise NAD+ inside cells, or does it only deliver precursors? The one human pharmacokinetic study showed the dose disappearing from plasma and reappearing as breakdown products and urinary excretion, and no human study has measured tissue or intracellular NAD+ after an infusion.
If the molecule is dismantled at the cell surface anyway, is there any advantage to infusing NAD+ over taking an oral precursor, which is cheaper, better studied and better tolerated? No head-to-head efficacy trial exists; the only direct comparison measured tolerability and favoured nicotinamide riboside.
Do the heart failure results replicate, and do they have anything to do with the wellness product? That trial used 10 milligrams a day at a single centre, roughly fiftyfold below clinic doses, and its secondary endpoints all fell short of significance.
What causes the cramping, vomiting and chest pressure during a fast infusion, and is the chest pressure cardiac in origin? No study has characterised the mechanism or monitored cardiac rhythm through a standard wellness drip.
What happens with repeated high-dose infusions over years, particularly regarding the tumorigenesis and senescence risks named in the 2020 benefit-risk review? No study of injected NAD+ has followed anyone beyond six months.